This is therefore a contrasting of the profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation in Catalyst Biosciences Inc. (NASDAQ:CBIO) and Protalix BioTherapeutics Inc. (NYSEAMERICAN:PLX). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Biosciences Inc.	N/A	21147.00	30.05M	-3.01	0.00
Protalix BioTherapeutics Inc.	34.24M	1.86	26.46M	-0.35	0.00

Table 1 highlights Catalyst Biosciences Inc. and Protalix BioTherapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows Catalyst Biosciences Inc. and Protalix BioTherapeutics Inc.’s return on assets, return on equity and net margins.

	Net Margins	Return on Equity	Return on Assets
Catalyst Biosciences Inc.	0.00%	-22.7%	-21.8%
Protalix BioTherapeutics Inc.	-77.28%	0%	0%

Institutional & Insider Ownership

Institutional investors owned 74.9% of Catalyst Biosciences Inc. shares and 9.74% of Protalix BioTherapeutics Inc. shares. About 0.3% of Catalyst Biosciences Inc.’s share are owned by insiders. Competitively, 6.23% are Protalix BioTherapeutics Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Catalyst Biosciences Inc.	-2.61%	-2.5%	-18.54%	-20.5%	-67.41%	8.62%
Protalix BioTherapeutics Inc.	0.54%	-0.25%	16.48%	-1.1%	-27.64%	55.88%

For the past year Catalyst Biosciences Inc. was less bullish than Protalix BioTherapeutics Inc.

Summary

On 6 of the 9 factors Protalix BioTherapeutics Inc. beats Catalyst Biosciences Inc.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase II clinical trials to treat cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase II clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.